Donate to Illuminate Contact TSF
Visit us on Facebook Visit us on Twitter Visit us on YouTube Visit us on Instagram Visit us on Linkedin Visit us on Tiktok
Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder

Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder

Journal: CNS Drugs; September 7, 2022

Author(s): Tina Nie & Hannah A. Blair

A review of inebilizumab treatment in NMOSD

Inebilizumab is approved for use as an intravenous infusion for treatment of adult NMOSD patients who test positive for AQP4 antibodies. Clinical trials found inebilizumab more effective than placebo at preventing NMOSD relapses. It also prevented worsening of disability scores and decreased the number of NMOSD-related hospitalizations and MRI lesions. However, it did not significantly improve low-contrast binocular vision. The clinical benefit of inebilizumab was maintained long-term (≥ 4 years in the open-label extension of the clinical trial). Inebilizumab was generally well tolerated, with most adverse events being mild to moderate in severity. The most common adverse events were urinary tract infection and joint pain. Inebilizumab provides an effective option for preventing NMOSD attacks in adults who are aquaporin-4 (AQP4)-antibody seropositive.

Free Access: Full-text + plain-language summary

read the full text

Industry Partners

Community Partners

WARNING: Internet Explorer does not support modern web standards. This site may not function correctly on this browser and is best viewed on Chrome, Firefox or Edge browsers. Learn More.